[Form 4] Aptevo Therapeutics Inc Insider Trading Activity

Rhea-AI Filing Summary

Aptevo Therapeutics director Barbara Lopez Kunz was granted 7,200 Restricted Stock Units (RSUs) on 08/06/2025. Each RSU converts one-for-one into common stock and the award vests in full on the first anniversary of the grant date. The reported position is held directly and the RSUs are recorded with a $0 per-share conversion price as described in the filing.

Insights

Corporate Governance Expert

TL;DR: Routine director equity grant—7,200 RSUs vesting after one year, aligning long-term interests but not an immediate equity transfer.

The filing documents a standard restrictive equity award to a director rather than an open-market purchase or sale. The RSUs convert on a one-for-one basis to common stock and vest in full on the first anniversary of the grant, which means no immediate increase in outstanding shares until vesting occurs. Ownership is recorded as direct, and the RSUs show a $0 conversion price consistent with typical restricted awards. From a governance viewpoint, this is a common practice to align director incentives with shareholders without immediate dilution.

Securities Analyst

TL;DR: Non-cash compensation grant to a director—7,200 RSUs; materiality depends on company share count, but filing itself is routine.

The transaction code indicates an acquisition of derivative securities in the form of RSUs. The filing specifies 7,200 RSUs underlying 7,200 common shares upon conversion and lists the transaction date as 08/06/2025. Because the award vests one year after grant, there is no immediate transfer of common shares reported here. The $0 listed for the RSU conversion reflects the standard administrative treatment of restricted awards. This is a routine insider compensation disclosure rather than a market-moving sale or purchase.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kunz Barbara Lopez

(Last) (First) (Middle)

2401 4TH AVENUE

SUITE 1050

(Street)

SEATTLE WA 98121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aptevo Therapeutics Inc. [ APVO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/06/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	08/06/2025		A		7,200		(2)	(2)	Common Stock	7,200	$0	7,200	D

Explanation of Responses:

1. Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.

2. The RSUs vest in full on the first anniversary of the date of grant.

	/s/ SoYoung Kwon, Attorney-in-Fact	08/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Aptevo (APVO) disclose in this Form 4 filing?

The filing shows director Barbara Lopez Kunz was granted 7,200 RSUs on 08/06/2025, which convert 1-for-1 into common stock and vest in full after one year.

Do the RSUs reported for APVO immediately increase common shares outstanding?

No. The RSUs convert to common stock only upon vesting; the filing notes the award vests in full on the first anniversary of the grant.

What is the conversion price or cost reported for the RSUs in the APVO filing?

The filing records the RSUs with a conversion indication of $0, consistent with restricted units that convert to shares rather than representing a purchase price.

How is the beneficial ownership described for the reported RSUs in the APVO Form 4?

The RSUs and the resulting common shares are reported as held directly by the reporting person.

When will the reported RSUs for APVO become exercisable or convertible?

The RSUs vest in full on the first anniversary of the grant date, at which point they convert one-for-one into common stock per the filing.